Key Documents

View All Documentation

SML1380

Sacubitril calcium salt

Name: Sacubitril calcium salt
Brand: SIGMA

≥98% (HPLC), metallo-endopeptidase neprilysin inhibitor, powder

Synonym(s):

(2R,4S)-4-[(3-Carboxy-1-oxopropyl)amino]-4-[(p-phenylphenyl)methyl]-2-methylbutanoic acid ethyl ester, 4-[[(2S,4R)-5-Ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoic acid calcium salt, 4-{[(2S,4R)-1-(4-Biphenylyl)-5-ethoxy-4-methyl-5-oxo-2-pentanyl]amino}-4-oxobutanoic acid; (2R,4S)-5-(Biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2-methylpentanoic acid ethyl ester, AHU-377 calcium salt, AHU377 calcium salt

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₂₄H₂₈NO₅ · 0.5Ca

CAS Number:

1369773-39-6

Molecular Weight:

430.52

UNSPSC Code:

12352200

NACRES:

NA.77

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

100

Storage condition:

desiccated

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

Product Name

Sacubitril calcium salt, ≥98% (HPLC)

Quality Level

100

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 10 mg/mL, clear

storage temp.

−20°C

SMILES string

[Ca+2].N([C@@H](C[C@@H](C)C(=O)OCC)Cc3ccc(cc3)c4ccccc4)C(=O)CCC(=O)[O-].N([C@@H](C[C@@H](C)C(=O)OCC)Cc1ccc(cc1)c2ccccc2)C(=O)CCC(=O)[O-]

InChI key

DDLCKLBRBPYKQS-OXXXZDCLSA-L

Description

Biochem/physiol Actions

Sacubitril (AHU377) is a prodrug inhibitor of the membrane metallo-endopeptidase neprilysin.

Sacubitril (AHU377) is a prodrug inhibitor of the membrane metallo-endopeptidase neprilysin. Sacubitril forms half of the heart failure combination drug LCZ696, along with the angiotensin-receptor blocker Valsartan. Sacubitril (AHU377) is cojnverted by esterases into the active inhibitor LBQ657, which prevents neprilysin′s degradation of atrial and brain natriuretic peptide, two blood pressure lowering peptides. The AHU377 valsartan combination drug LCZ696 showed a reduction in the risk of cardiovascular death of 20% compared to the standard ACE inhibitor enalapril, and also a 21% drop in the risk of hospitalization.